Claims for Patent: 4,957,922
✉ Email this page to a colleague
Summary for Patent: 4,957,922
Title: | Infusion solutions of 1-cyclopropyl-6-fluoro-1,4-di-hydro-4-oxo-7-(1-piperazinyl)-quinoline-3- carboxylic acid |
Abstract: | An aqueous infusion solution containing 0.015 to 0.5 g of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-car box ylic acid per 100 ml of aqueous solution and an amount of at least one physiologically tolerated acid which suffices to dissolve the active compound. |
Inventor(s): | Lammens; Robert F. (Leverkusen, DE), Mahler; Hans F. (Colonge, DE), Serno; Peter (Colonge, DE) |
Assignee: | Bayer Aktiengesellschaft (Leverkusen, DE) |
Application Number: | 07/329,922 |
Patent Claims: |
1. An aqueous infusion solution comprising 0.015 to 0.5 g of an active compound, said active compound being
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-car boxylic acid, per 100 ml of aqueous solution and an amount of at least one physiologically tolerated acid which suffices to dissolve the active compound, wherein there are 1.33 to
2.2 moles per mole of active compound, of the physiologically tolerated acid, the physiologically tolerated acid being selected from the group consisting of hydrochloric acid, methanesulphinc acid, propionic acid, succinic acid, glutaric acid, citric
acid, fumaric acid, maleic acid, tartaric acid, glutamic acid, gluconic acid, glucuronic acid, galacturonic acid, ascorbic acid, phosphoric acid, nitric acid, acetic acid, malic acid, L-aspartic acid and lactic acid.
2. An infusion solution according to claim 1, containing a mixture of physiologically tolerated acids to dissolve the active compound. 3. An infusion solution according to claim 1, wherein the physiologically tolerated acid is selected from the group consisting of lactic acid, hydrochloric acid and mixtures of lactic acid and hydrochloric acid. 4. An infusion solution according to claim 1, containing 1.33 to 1.50 mols of lactic acid per mol of active compound. 5. An infusion solution according to claim 1, having a pH from 3 to 5.2. 6. An infusion solution according to claim 1, having a pH from 3.6 to 4.7. 7. An infusion solution according to claim 1, having a pH from 3.9 to 4.5. 8. An infusion solution according to claim 1, having a pH from 4.1 to 4.3. 9. An infusion solution according to claim 1, which is substantially isotonic. 10. An infusion solution according to claim 1, containing 1.33 to 2.2 mols of lactic acid and 0.0 to 0.80 mol of hydrochloric acid per mol of active compound, and relative to 100 ml of solution, 0.6 to 2.2 g of NaCl. 11. An infusion solution according to claim 1, containing 1.33 to 1.4 mols of lactic acid and 0.0 to 0.80 mol of hydrochloric acid per mol of active compound, and relative to 100 ml of solution, 0.75 to 1.2 g of NaCl. 12. An infusion solution according to claim 1, present in a container in from 40 to 600 ml. 13. An infusion solution according to claim 1, wherein the physiologically tolerated acid is lactic acid. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.